We conducted a prospective quality-of-life analysis during outpatient immunotherapy in 22 patients with progressive metastatic renal cell carcinoma (RCC) treated with subcutaneous interferon-α2a and subcutaneous interleukin-2. Here, IGKV2D-29 is linked to renal cell carcinoma.